Morishita Jintan Co., Ltd. (4524) AI Stock Analysis

• Market Cap: ¥8.68B
• Dividend Yield: 2.58%
• Average Volume (3M): 2.15K
• Price to Earnings (P/E): 18.7
• Beta (1Y): 0.40
• Revenue Growth: -0.09%
• EPS Growth: -29.95%
• Country: JP
• Employees: 354
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 39.87
• Shares Outstanding: 4,150,000
• 10 Day Avg. Volume: 1,670
• 30 Day Avg. Volume: 2,150
• PEG Ratio: -0.73
• Price to Book (P/B): 0.71
• Price to Sales (P/S): 0.68
• P/FCF Ratio: 125.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 65 Neutral
• Price Target: ¥2,338.00 ▲(8.74% Upside)

Morishita Jintan Co., Ltd. has a strong financial foundation with robust revenue growth and efficient cost management. However, technical indicators suggest bearish momentum, which could pose short-term risks. The valuation is fair, providing a balanced view of the stock's potential. The absence of recent earnings call data or notable corporate events limits additional insights.

Morishita Jintan Co., Ltd. Business Overview & Revenue Model

Company Description

Morishita Jintan Co., Ltd. (4524) is a Japanese pharmaceutical company primarily engaged in the development, manufacturing, and marketing of various healthcare products, particularly focusing on traditional herbal medicines, over-the-counter drugs, and dietary supplements. The company operates in the healthcare sector, emphasizing the integration of traditional practices with modern science to produce effective health solutions. Morishita Jintan is known for its commitment to quality and innovation in the pharmaceutical industry.

How the Company Makes Money

Morishita Jintan generates revenue through multiple key streams, including the sale of its pharmaceutical products, dietary supplements, and herbal medicines. The company capitalizes on its strong brand reputation and extensive distribution network to reach both domestic and international markets. Additionally, it may engage in partnerships with other pharmaceutical companies for research and development, co-marketing agreements, and licensing deals, which contribute to its earnings. The company's focus on innovation and quality also allows it to command premium pricing for its products, enhancing its profitability.

Morishita Jintan Co., Ltd. Financial Statement Overview

Summary

Morishita Jintan Co., Ltd. exhibits solid financial health with growth in revenues and effective cost management leading to strong margins. The balance sheet strength is highlighted by low leverage and high equity, while cash flow management shows improvement in free cash flow. Overall, the company is well-positioned for sustained financial performance, though attention should be given to maintaining net profit margins.

Income Statement

Morishita Jintan Co., Ltd. demonstrates robust revenue growth over the years, with a notable increase from 2022 to 2025. The company maintains a healthy gross profit margin, indicative of efficient production and pricing strategies. However, the net profit margin saw a decline in 2025, suggesting increased operational costs or other expenses. EBIT and EBITDA margins remain strong, underscoring operational efficiency.

Balance Sheet

The company has a strong balance sheet with a high equity ratio, reflecting financial stability and low reliance on debt financing. The debt-to-equity ratio is low, indicating prudent financial management. Return on equity is healthy, showcasing effective use of shareholder funds to generate profits.

Cash Flow

Operating cash flow has generally been positive, showing good cash generation from core operations. Free cash flow fluctuated, with a significant recovery in 2025, hinting at improved capital expenditure management. The operating cash flow to net income ratio is favorable, suggesting good cash conversion efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	12.70B	12.77B	12.41B	11.36B	9.56B	9.43B
Gross Profit	5.80B	5.79B	6.00B	5.31B	4.88B	4.79B
EBITDA	1.11B	1.36B	1.29B	1.25B	977.00M	814.00M
Net Income	465.00M	547.00M	697.00M	491.00M	283.00M	206.00M
Balance Sheet
Total Assets	17.49B	17.90B	17.18B	16.10B	14.48B	14.45B
Cash, Cash Equivalents and Short-Term Investments	1.13B	1.94B	1.09B	2.41B	2.14B	2.70B
Total Debt	1.33B	1.36B	425.00M	537.00M	786.00M	1.30B
Total Liabilities	5.51B	5.74B	5.04B	4.71B	4.03B	4.17B
Stockholders Equity	11.98B	12.15B	12.14B	11.39B	10.45B	10.27B
Cash Flow
Free Cash Flow	0.00	69.00M	-455.00M	715.00M	-159.00M	284.00M
Operating Cash Flow	0.00	669.00M	196.00M	1.18B	543.00M	871.00M
Investing Cash Flow	0.00	-701.00M	-1.15B	-474.00M	-463.00M	-502.00M
Financing Cash Flow	0.00	880.00M	-362.00M	-433.00M	-645.00M	-141.00M

Morishita Jintan Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2150.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4524, the sentiment is Negative. The current price of 2150 is below the 20-day moving average (MA) of 2159.70, below the 50-day MA of 2197.60, and above the 200-day MA of 2135.99, indicating a bearish trend. The MACD of -17.57 indicates Positive momentum. The RSI at 25.63 is Positive, neither overbought nor oversold. The STOCH value of 2.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4524.

Morishita Jintan Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4524	―	¥8.68B	18.72	―	2.58%	-0.09%	-29.95%
4539	―	¥6.01B	15.20	―	2.99%	5.18%	―
4582	―	¥6.31B	―	―	―	-50.27%	-3.33%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4892	―	¥5.49B	―	―	―	8.12%	-19.12%
4512	―	¥10.13B	-310.28	―	1.04%	4.00%	-933.04%
4586	―	¥7.54B	―	―	―	-82.19%	-106.15%